Drugs / JWCAR239
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07024147 | Jul 2025 → Jul 2027 expected | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-09 | Shanghai JW Therapeutics Co., Ltd. | ASGCT 2026 | JW Therapeutics Presents Preclinical Data of JWCAR201 and JWCAR239 at the 29th Annual Meeting of the American Society of Gene & Cell Therapy jwtherapeutics.com ↗ |
| 2025-09-25 | Shanghai JW Therapeutics Co., Ltd. | JW Therapeutics Completes First Patient Infusion in Clinical Study of JWCAR239 for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma jwtherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JWCAR239 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07024147 ↗ |
| Modality | Cell therapy | “JWCAR239 is a CD19/CD20 CAR-T product.” NCT07024147 ↗ |
| Route | Intravenous | “JWCAR239 administered as a single IV infusion” NCT07024147 ↗ |